ASCO 2022: Investigational N-803 Offers New Hope for Patients With Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG
Results among patients with carcinoma in situ compared positively with pembrolizumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.